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ABSTRACT: 
Neurodegenerative  diseases,  in  particular  Alzheimer  disease  (AD),  afflict  an  increasing 
proportion of the older population with aging. Decreased exposure to sunlight and decreased 
consumption of fish, fruits, and vegetables, are two epidemiological factors that appear to be 
related to the pandemic of AD. In addition to replacing simple with complex carbohydrates and 
avoiding saturated fat, two nutritional components, vitamin D (acting through the endogenous 
hormonal form 1,25 dihydroxyvitamin D, 1,25D) and docosahexaenoic acid (DHA) (acting 
through the docosanoid lipidic modulators resolvins and neuroprotectins) have high potential for 
prevention of Alzheimer disease. 1,25D is a neuroprotective, it acts both directly and indirectly 
in neurons by improving the clearance of amyloid-beta by macrophages/microglia. Resolvins and 
neuroprotectins  inhibit  amyloidogenic  processing  of  amyloid-precursor  protein,  inflammatory 
cytokines, and apoptosis. It is likely that the increased consumption of vitamin D and fish oil 
could prevent neurodegeneration in some subjects by maintaining adequate endocrine, paracrine, 
and/or  autocrine  production  of  1,25D  and  the  DHA-derived  lipidic  modulators.  Before  firm 
recommendations of the dosage can be proposed, however, the in vivo effects of vitamin D3 and 
DHA supplementation should be investigated by prospective studies.  
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REVIEW: 
Alzheimer disease (AD) is the leading cause of dementia worldwide. The major neuropathology 
of AD is related to amyloid-β 1-42 (A), a peptide cleaved from the Amyloid precursor protein. 
The upstream causes of the most common sporadic form of AD are thought to include oxidative 
stress, dyslipidemia, insulin resistance, physical and psychological stress, and lack of physical Functional Foods in Health and Disease 2011; 12:545-554                                                              Page 546 of 554 
 
 
and mental exercise in subjects with the E4 allele of the lipid transport protein apolipoprotein E 
(ApoE) [1]. The downstream mechanisms of AD are considered to include (a)  brain amyloidosis 
with both fibrillar and oligomeric A with related synapse loss [2],  as described  by the amyloid 
hypothesis [3]; (b) hyperphosphorylation of tau leading to neurofibrillar tangles [4]; and (c) brain 
inflammation [5]. Although no disease-modifying therapy is available, preventive therapy could 
address the epidemiological factors associated with AD, i.e. decreased exposure to sunlight, and 
decreased consumption of fish, fruits, and vegetables.  
  As recommended for optimal health, nutritional prevention of AD should include a diet 
with a low amount of saturated fat, and high proportion of complex carbohydrates from cereals 
and vegetables, such as the Mediterranean diet, with the addition of phytochemicals and other 
functional food components.  In fact,  greater adherence to the Mediterranean diet and higher 
physical activity were independently associated with reduced risk of AD [6].  Anti-oxidants, 
such as vitamin C and vitamin E, should be included in the diet in physiological amounts [7]. A 
low cholesterol diet is important because the cholesterol oxidation products, i.e. oxysterols, have 
pro-inflammatory properties [8]. Patients with diabetes mellitus type II have an increased risk of 
AD, which could  be related to  a diet high in calories,  or to  the metabolic complications  of 
diabetes [9].  
In principle, phytochemicals could be protective against AD due to their antioxidant, anti-
inflammatory and hypolipidemic properties, including inhibition of (a) protein kinases, such as 
Akt/protein kinase B (Akt/PKB), Janus kinase 1 (JAK1), glycogen synthase kinase 3 (GSK) [10] 
[11], (b) dysregulated insulin signaling [12], and (c) cytokines stimulating phosphoinositide 3 
kinase (PI3K), GSK, and protein kinase C (PKC) [13].  
Chronic diseases are complex and regulated by multiple genes mandating careful and 
multitargeted  selection  of  phytochemicals.  Although  there  was  initial  excitement  about 
curcuminoids based on epidemiological data in India and Singapore [14], curcuminoids were not  
effective in a double-blind trial in AD patients at UCLA [15]. It has become clear that molecular 
and immunological effects of phytochemicals need to be understood before they can be used for 
therapy. For example, while curcuminoids have beneficial immune effects on A phagocytosis at 
0.1 µM, they cause apoptosis at 1 µM [16].  Furthermore, the heterogeneity of AD mandates that 
therapy should be personalized in patients with macrophages of different types (Type 0, I and II), 
as discussed below. Nonetheless, because immune cells migrate from the blood into the brain, 
improvement of immune cell function stands out as a therapeutic target.  
 
Immunopathology  and  immunotherapy  for  Alzheimer  disease:  Brain  amyloidosis  is  a 
neuropathological hallmark of AD, and clearance of brain amyloidosis has been the goal of 
therapies by A vaccine and anti- A antibodies [17]. The vaccine and antibodies are designed to 
stimulate the adaptive immune system for the enhancement of A phagocytosis by microglia and 
macrophages. The immunopathology of AD patients also involves the innate immune system, 
which has not been the prime target of the vaccine. The macrophages of normal subjects are able 
to  phagocytize  and  degrade  A,  but  the  macrophages  of  AD  patients  are  defective  in 
phagocytosis and degradation, specifically of A (not of bacteria) [18]. Although the A vaccine 
effectively increased A clearance in animal models, it failed in patients due to pathological Functional Foods in Health and Disease 2011; 12:545-554                                                              Page 547 of 554 
 
 
effects related to tau and amyloid angiopathy [19], lack of clinical efficacy, and encephalitis in 
6% of patients [20]. Thus, improving the innate immune system of patients is a novel approach 
to AD.  
We have observed that 1,25D3, DHA and DHA-derived lipid modulators are effective in 
vitro in recovering dysregulated phagocytosis of A by AD macrophages. However, the benefits 
of  supplementation  with  vitamin  D3  or  DHA  in  vivo  have  not  been  uniformly  positive  in 
prospective  studies,  suggesting  that  the  enzymes  responsible  for  the  anabolic  production  of 
1,25D3  and  resolvins  by  PBMCs/macrophages  may  be  defective  in  the  patients  with 
neurodegenerative diseases.  In this respect, we have observed a significant down-regulation of 
-OHase in PBMCs of a patient with amyotrophic lateral sclerosis (treated with 
SOD-1),  when  compared  to  controls  treated  in  an  identical  manner.  Therefore,  nutritional 
therapy may need to be personalized. 
 
Neuroprotective  and  immune  effects  of  vitamin  D  and  curcuminoids  against  dementia: 
Numerous studies  have  shown an  association of vitamin D insufficiency  with dementia and 
cognitive decline [21]. Causal relation to dementia was suggested in two prospective studies: the 
study of 858 older Italian adults indicated relative risk (RR) of cognitive decline (RR 1.6) in 
subjects with severe 25 (OH)vitamin D insufficiency (<25nM) [22]; the study of 1136 older US 
men  found  increased  odds  of    cognitive  decline  (OR  1.41)  in  those  with  <  49  nM  25 
(OH)vitaminD [23].    
1,25D has several intra-cranial mechanisms important for brain health. 1,25D modulates, 
through the nuclear vitamin D receptor (VDR), the transcription of as many as 500-1000 genes 
[24]. 1,25D3 protects against neurotoxicity of A by downregulating in cortical neurons through 
VDR  L-type  voltage-sensitive  calcium  channels,  LVSCC-A1C  and  LVSCC-A1D,  and 
upregulating nerve growth factor (NGF) and VDR [25]. The role of VDR suppression in AD was 
highlighted  by  the  demonstration  that  VDR  suppression  by  siRNA  results  in  an  increase  of 
LVSCC-A1C and a decrease of NGF production without a change in LVSCCA1D [26].   
As mentioned, the extra-cranial mechanisms of 1,25D3 involve, in particular, the innate 
immune system cells, macrophages, and microglia.   Macrophages are immune cells that locally 
produce 1,25D, given that they, like keratinocytes, contain all components of the vitamin D 
phytoendocrine  system  [27].  1,25D  regulates  anti-microbial  macrophage  function  through 
potentiation of interferon-gamma production by T cells [28]. 1,25D3 repairs the deficiency in 
phagocytosis  of  A  by  AD  macrophages  through  VDR  genomic  as  well  as  nongenomic 
mechanisms [16]. MGAT3 (GnT3) is an essential gene for phagocytosis of A by macrophages, 
as demonstrated using MGAT3 (GnT3) siRNA to block A phagocytosis.  We have found that 
the  macrophages  of  AD  patients  could  be  distinguished  according  to  MGAT3  (GnT3) 
transcriptional responses to A into Type I, II and 0 as follows: Type I macrophages down 
regulate MGAT3 and TLR-3 but are stimulated by curcuminoids to up regulate these genes; Type 
II  macrophages  up  regulate  MGAT3  and  TLR-3,  but  these  genes  are  down  regulated  by 
curcuminoids;  Type  0  macrophages  are  transcriptionally  –inhibited  and  do  not  respond  to 
stimulation [29]. 1,25D3 increased phagocytosis of A by macrophages of both Type I and Type 
II patients. Bisdemethoxycurcumin had small additive effect only in Type I cells [16].  Functional Foods in Health and Disease 2011; 12:545-554                                                              Page 548 of 554 
 
 
The in vitro mechanisms of 1,25D3 involve potentiation of the currents of the chloride 
channel named ClC-3 in both Type I and II macrophages.  Furthermore, 1,25D3 elicits a stronger 
up-regulation of ClC-3 and VDR mRNA’s in Type II cells than Type I cells, and possibly has a 
stronger effect on A phagocytosis (Mizwicki, Fiala et al, JAD in press). Although there is no 
firm data on the differences between patients with Type I and II macrophages in vivo, anecdotal 
observations suggest that patients differ in responses to vitamin D3 supplementation [29].     
Regarding  the  dosage  and  adverse  effects  of  vitamin  D,  hypercalcemia  has  been  of 
concern, however, this has not been documented with administration of vitamin D3 < 10,000 
IU/day (1 IU= 25 ng vitamin D3) or whole body sunlight exposure (equivalent to 10,000 -20,000 
IU vitamin D3). The dose of vitamin D3 recommended by the Institute of Medicine is 600 IU 
before the age 70 years and 800 IU after the age 70 years. To the subjects at risk of deficiency 
because of race, pregnancy, disease states, obesity, medications, or old age, a higher dose of 
vitamin D3 should be administered [30]. In these subjects, at least 1,500 - 2000 IU per day are 
necessary to maintain vitamin D sufficiency (25-hydroxyvitamin D3 serum level > 30 ng/ml), but 
higher doses may be beneficial.  In our experience, an AD patient with Type II macrophages has 
been relatively cognitively stable  (Mini-Mental State Examination score (MMSE), 19-20) for 3 
years on daily supplementation with 5,000 I.U. of vitamin D3  and 1 gm DHA [29].  
 
Neuroprotective mechanisms of docosahexaenoic acid, resolvin D1 andneuroprotectin D1: 
Docosahexaenoic  acid  (DHA;  4Z,7Z,10Z,13Z,16Z,19Z-docosa-4,7,10,13,16,19-hexaenoic  acid) 
22:6(n-3) is a major omega-3 fatty acid in neurons, which are essential for brain growth and 
development.  In  the  brain,  DHA  has  effects  on  membrane  fluidity,  synaptic  function,  and 
structural integrity and has anti-inflammatory activity [31] via inhibition of calcium channels 
excitotoxicity [32], and activation of selective gene transcription [33].  In an observational study, 
high intake of DHA increased gray matter in corticolimbic circuitry [34]. DHA is a precursor for 
the anti-inflammatory lipid mediators called resolvins, protectins, and neuroprotectins, which 
have  recently  been  reviewed  [35-37].  The  E  series  resolvins,  e.g  resolvin  E1  (RvE1; 
5S,12R,18R-trihydroxy-6Z, 8E, 10E, 14Z, 16E eicosapentaenoic acid) are biosynthesized from 
the omega-3 fatty acid eicosapentaenoic acid (EPA) 20:5(n-3), and the D series resolvins, e.g. 
resolvin D1 (RvD1; 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) from 
DHA by transcellular synthesis facilitated by aspirin in vascular, leukocytic, and neural cells 
[38].  Neuroprotectin  D1  (NpD1;  10R,17S-dihydroxy-docosa-4Z,7Z,11E,15E,19Z  hexaenoic 
acid) is  a potent lipidic mediator induced in the brain after injury, oxidative stress, or stimulation 
by  neurotrophins,  which  release  DHA  through  phospholipase  A2  (PLA2)  from  neuronal 
membrane phospholipids. NPD1 is generated from DHA by 15-lipoxygenase-1, epoxidation and 
hydrolysis.    NPD1  has  multiple  neuroprotective  activities,  such  as  down  regulation  of 
inflammatory  genes,  attenuation  of  leukocyte  infiltration,  inhibition  of  apoptosis,  and 
neurotrophic effects through amyloid- precursor protein (APP)-derived peptide called sAPP 
via  a  non-amyloidogenic,  -secretase–mediated  pathway  [39]  [40].  On  the  other  hand, 
arachidonic acid (omega-6) in neuronal membranes generates through cyclooxygenase-2 (COX-
2)  the  pro-inflammatory  mediators  prostaglandin  E2  (PGE2),  prostaglandin  I2  (PGI2),  and 
thromboxane A2 [41]. The binding of PGE2 to the E1 receptor is neurotoxic through disruption of Functional Foods in Health and Disease 2011; 12:545-554                                                              Page 549 of 554 
 
 
calcium  homeostasis,  whereas  binding  of  PGE2  to  the  EP2  receptor  is  neuroprotective  [42]. 
Other  mechanisms  of  DHA  include  reducing  A  production  by  increasing  transthyretin  and 
suppression of phosphorylation of tau [43].   
         DHA may alter amyloidogenic processing by facilitating the interaction of -secretase with 
APP and processing of APP through the nonamyloidogenic pathway [44]. DHA activates pro-
survival  signaling  of  Akt  by  membrane  translocation  [45].  DHA  interacts  with  the  nuclear 
receptors called retinoid X receptors (RXRs) and peroxisome proliferator-activated receptor-γ 
(PPAR-γ). RXR/PPAR-γ heterodimers inhibit multiple inflammatory mediators [46].  
In some clinical studies, DHA has been shown to be neuroprotective,includingtraumatic 
brain  injury  [47],  stroke  [48],  and  cognitive  decline  in  14  of  17  observationalstudies  [49].  
Supplementation with omega-3 fatty acids for 6 months reduced release of IL-1 and IL-6 from 
PBMC’s of AD patients [50], but this was refuted in a subsequent study [51]. In randomized, 
double blind clinical trials the overall results of DHA supplementation vs. placebo have been 
negative,  but  suggestive  of  efficacy  in  early  cases  and  especially  in  Apo4  non-carriers. 
However, in a recent 18-month prospective study algal DHA supplementation, however without 
attention to n-6/n-3 ratio, did not slow the rate of cognitive and functional decline in patients 
with mild to moderate AD (MMSE scores, 14-26), although restricted effect on the ADAS-cog 
and  MMSE  was  observed  in  Apo4  non-carriers  [52].  Thus,  the  confounding  factors  in  the 
studies of omega-3 fatty acids are believed to be related to: (a) the degree of neurodegeneration , 
(b) high dietary n-6 intake, (c) Apo E4 status, (d) oxidation status of the omega-3 fatty acids 
[49]. The source and stability of the omega 3 fatty acids may be of importance. The company 
Smartfish ( Oslo, Norway) have tested their drink composion which contains omega 3 from fresh 
locally harvested fish,  and found no oxidation products for as long as 1 year after expiration. 
Nutritional  supplementation  with  DHA  has  had  greatest  impact  on  cardiovascular 
prevention, especially prevention of arrhytmias, when the n-6/n-3 ratio was lowered to 1 [41]. 
The dietary recommendations for lowering the ratio include eliminating N-6 (linoleic acid)-rich 
foods  (e.g.  corn,  peanut,  soybean,  sunflower  and  safflower  oils,  margarine,  and  meats),  and 
increasing  N-3  (alpha-linolenic)-rich  foods  (canola  oil,  linseed  oil)  and  especially  N-3  and 
EPA+DHA-rich foods, (herring, salmon, and tuna with low mercury content). There have been 
caveats of high serum DHA level association with increased risk of high-grade prostate cancer 
[53]  and  with  dementia  [54].  However,  DHA  serum  levels  do  not  determine  the  health 
consequences,  because  the  derivation  of  pro-  and  anti-inflammatory  mediators  from  DHA 
depends on local enzymes in tissues. Nevertheless, administration of polyunsaturated fatty acids, 
in particular omega-6 but also omega-3, is not without problems: non-enzymatic oxidation of 
EPA  and  DHA  leads  to  the  formation  of  isoprostanes  and  further  chain  cleavage  yields 
aldehydes,  such  as  malondialdehyde  (MDA),  acrolein,  and  hydroxyalkenals,  such  as  4-
hydroxynonenal, which can impair the function of nervous cells [8].   
  
Clinical  use  of  vitamin  D3  and  DHA:  Although  the  effects  in  animal  models  provide 
perspective on biochemical mechanisms, such mechanisms have to be shown to be relevant to 
human patients. As mentioned, AD patients have defects in the innate immune system for A 
phagocytosis, which have not been reproduced in animal models. In addition a mouse VDR Functional Foods in Health and Disease 2011; 12:545-554                                                              Page 550 of 554 
 
 
responds differently to VDR transcriptional modulators than does the human VDR  [55]. For 
example the MK analogue that blocks 1,25D3 transactivation in a number of different cell types 
and  1,25D3-induced  phagocytosis  of  Aβ  by  AD  macrophages,  does  not  block  1,25D3-VDR 
transactivation in rodent cells [56].  Furthermore, it has been demonstrated that regulation of the 
cathelicidin  antimicrobial  peptide  (CAMP)  gene  by  VDR  and  its  ligand  1,25D3  is  not 
evolutionarily conserved in mice, rats, or dogs, because the promoters of their CAMP genes lack 
a VDR response element (VDRE) [57]. Therefore, it is quite clear that the results in mouse 
model  cannot  be  applied  to  AD  patients  and  must  be  determined  in  prospective  studies  of 
persons at risk. 
 
CONCLUSIONS: 
The combined use of vitamin D3 and DHA is an emerging novel strategy to enhance direct and 
immune  protection  of  neurons  against  brain  amyloidosis  and  other  brain  insults.  These  two 
compounds will likely have preventive effects in the early stage of neurodegeneration, rather 
than therapeutic effects.  
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